Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3464-3470

  Gerber, Bernd ^a   Krause, Annette ^a   MÜller, Heiner ^a   Reimer, Toralf ^a   KÜlz, Thomas ^a   Makovitzky, Josef ^a   Kundt, Guenter ^a   Friese, Klaus ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING;

EID: 0034668093     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3464     Document Type: Article

References (49)

1. Recent advances in adjuvant therapy of breast cancer
2. Tamoxifen: The treatment of choice - Why look for alternatives?
3. The 1998 St. Gallen's Consensus Conference: An assessment
4. Tamoxifen for early breast cancer: An overview of the randomised trials
5. Tamoxifen in the treatment of breast cancer
6. Use of tamoxifen for breast cancer: Twenty-eight years later
7. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
8. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
9. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer
10. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
11. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
12. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group
13. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients
14. Second cancers after adjuvant tamoxifen therapy for breast cancer
15. Risk of endometrial cancer after tamoxifen treatment of breast cancer
16. Gynecologic tumors in tamoxifen-treated women with breast cancer
17. Does tamoxifen cause cancer in humans?
18. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer
19. Surveillance for endometrial cancer in women receiving tamoxifen
20. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients
21. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen
22. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities
23. Uterine pathology in tamoxifen-treated patients with breast cancer
24. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen
25. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
26. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen
27. Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen
28. Benign and hyperplastic endometrial changes associated with tamoxifen use
29. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen
30. Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen
31. Tamoxifen and the endometrium: Findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients
32. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen
33. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening
34. Tamoxifen and endometrial pathologies: A prospective study
35. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen
36. Endometrial thickness in tamoxifen-treated patients: An independent predictor of endometrial disease
37. Long-term transvaginal ultrasonographic endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment
38. Effect of tamoxifen on endometrial proliferation
39. The rating of transvaginal sonography in the evaluation of postmenopausal bleedings
40. The effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study
41. Longitudinal hysteroscopic follow-up during tamoxifen treatment
42. Should tamoxifen users be screened for endometrial lesions?
43. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
44. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients
45. Endometrial polyps: A comparison study of patients receiving tamoxifen with two control groups
46. Optimizing the accuracy of transvaginal ultrasonography of the endometrium
47. Uterine side effects of tamoxifen: A need for systematic pretreatment screening
48. Endometrial cancer in polyps associated with tamoxifen use
49. Are vaginal bleedings in postmenopausal patients an early symptom of malignancies?